Tada,

one correction to your estimates.  If NNT is indeed 20, then the drug can be priced at almost $10,000 a year, not $2k.  The value of a MACE event seems to be put at $200,000 by insurance companies.  Therefore, they would be fine with up to $200,000/20 = $10,000 per year per patient.

A NNT of 20 would suggest far wider usage than the narrowly defined Low HDL/ACS patients with diabetes.  Off label use will most likely become rampant over time.

Iconoclast